Revelation Biosciences (REVB) announced safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease patients. The primary endpoint to evaluate the safety and ...
Location: Manchester Grand Hyatt, 1 Market Place, San Diego CA “We are pleased to have an opportunity to share our exciting clinical data for the treatment of CKD and AKI in this forum,” said James ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results